Publicaciones › Inteligencia artificial y análisis automático de imágenes
Real-world faricimab switch in France: artificial intelligence-based detection of changes in exudative signs in difficult-to-treat neovascular age-related macular degeneration
Detección en el mundo real de cambios en signos exudativos en degeneración macular relacionada con la edad neovascular difícil de tratar con faricimab en Francia mediante inteligencia artificial
| Año | 2025 |
|---|---|
| Fuente | BMJ open ophthalmology |
| Tipo | article · Journal Article, Multicenter Study |
| Autores (10) | Vincent Gualino, Charles Sohier, Maxime Sibert, Ali Erginay, Fanny Varenne, Jacqueline Butterworth, Aude Couturier, Pierre-Henry Gabrielle, Vincent Soler, Catherine Creuzot-Garcher |
| Posición de Erginay | 4 de 10 |
| Citas | 2 (OpenAlex) |
| Enlaces | DOI 10.1136/bmjophth-2025-002267 · PubMed 40550705 · OpenAlex · Texto completo en acceso abierto |
| Líneas | Inteligencia artificial y análisis automático de imágenes Edema macular diabético y sus tratamientos Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo |
En pocas palabras
Se estudió el efecto del tratamiento con faricimab en pacientes con degeneración macular relacionada con la edad neovascular que no respondían bien a otros tratamientos. Utilizando inteligencia artificial para medir los fluidos en la retina, se encontró que casi la mitad de los pacientes lograron una respuesta seca después de dos inyecciones. Esto sugiere que el faricimab puede ser una opción efectiva para estos pacientes.
Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.
Resumen original
Purpose Some patients with neovascular age-related macular degeneration (nAMD) have persistent signs of exudation under treatment with intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents. We examined the real-world anatomical responses among patients with suboptimal response and switched to faricimab using artificial intelligence (AI)-based retinal fluid quantification. Methods A retrospective, multicentric, cohort study of patients in France with exudative signs and switched to faricimab without a new loading phase, maintaining the same prior injection interval. The RetInSight Fluid Monitor AI software quantified subretinal (SRF) and intraretinal (IRF) fluid on spectral domain optical coherence tomography. The primary outcome was change in SRF and IRF volumes in the central 1 and 6 mm retinal areas after one and two injections of faricimab. Results 74 patients (74 eyes) were included (mean age: 81.5±8.4 years, 49% male). Significant reductions were observed in mean 1 mm IRF (−2.9±18.3 nl; p=0.002), mean 6 mm IRF (−17.7±71.1 nl; p<0.001) and mean 6 mm SRF (−24.8±156.3 nl; p<0.001) volumes after one injection. The proportion of dry eyes (<5 nl for SRF and IRF in the 1 and 6 mm areas) increased from 0% at baseline to 32.4% after one injection and 48.4% after two injections. Lower baseline SRF volumes were predictive of dry response after one injection ( adj OR 0.965; p=0.028) and lower baseline IRF volumes were predictive of dry response after two injections ( adj OR 0.373; p=0.051). Conclusion Nearly half of patients achieved a dry response after two injections. AI-assisted fluid quantification provided objective monitoring, identifying lower baseline SRF and IRF as predictive factors for good response. Limited patient inclusion means longer-term and larger prospective studies are now required using automated retinal fluid quantification to further refine the baseline characteristics of good switch responders to better adapt switch protocols.